Patents Assigned to ONCOSYNERGY, INC.
  • Anti-integrin ?1 antibody compositions and methods of use thereof
    Patent number: 11142576
    Abstract: The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin ?1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: October 12, 2021
    Assignee: Oncosynergy, Inc.
    Inventor: W. Shawn Carbonell
  • Anti-integrin ?1 antibody compositions and methods of use thereof
    Patent number: 10023638
    Abstract: The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin ?1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: July 17, 2018
    Assignee: Oncosynergy, Inc.
    Inventor: W. Shawn Carbonell
  • ANTI-INTEGRIN BETA-1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20140328830
    Abstract: The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin ?1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.
    Type: Application
    Filed: December 24, 2013
    Publication date: November 6, 2014
    Applicant: ONCOSYNERGY, INC.
    Inventor: W. Shawn Carbonell
  • MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS
    Publication number: 20140135290
    Abstract: The present invention includes macrocyclic prodrug compounds, pharmaceutical compositions containing them. The present invention also includes use of these compounds in the treatment of various diseases including an autoimmune disease, an inflammatory disease, a neurological or neurodegenerative disease, cancer, a cardiovascular disease, allergy, asthma, a hormone-related disease, and tumors or symptoms resulting from neurofibromatosis.
    Type: Application
    Filed: November 4, 2013
    Publication date: May 15, 2014
    Applicants: ONCOSYNERGY, INC., LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURG
    Inventors: James HECK, Nicolas Winssinger, John C. Chabala, Sofia Barluenga, Ruihong Chen, Allan Rubenstein, Jin-Chen Yu